LRSAM1 variants and founder effect in French families with ataxic form of Charcot-Marie-Tooth type 2.


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
09 2019
Historique:
received: 06 09 2018
accepted: 26 03 2019
revised: 17 03 2019
pubmed: 19 4 2019
medline: 13 6 2020
entrez: 19 4 2019
Statut: ppublish

Résumé

Currently only 25-30% of patients with axonal forms of Charcot-Marie-Tooth disease (CMT) receive a genetic diagnosis. We aimed to identify the causative gene of CMT type 2 in 8 non-related French families with a distinct clinical phenotype. We collected clinical, electrophysiological, and laboratory findings and performed genetic analyses in four different French laboratories. Seventy-two patients with autosomal dominant inheritance were identified. The disease usually started in the fourth decade and the clinical picture was dominated by sensory ataxia (80%), neuropathic pain (38%), and length-dependent sensory loss to all modalities. Electrophysiological studies showed a primarily axonal neuropathy, with possible isolated sensory involvement in milder phenotypes. Disease severity varied greatly but the clinical course was generally mild. We identified 2 novel variants in LRSAM1 gene: a deletion of 4 amino acids, p.(Gln698_Gln701del), was found in 7 families and a duplication of a neighboring region of 10 amino acids, p.(Pro702_Gln711dup), in the remaining family. A common haplotype of ~450 kb suggesting a founder effect was noted around LRSAM1 in 4 families carrying the first variant. LRSAM1 gene encodes for an E3 ubiquitin ligase important for neural functioning. Our results confirm the localization of variants in its catalytic C-terminal RING domain and broaden the phenotypic spectrum of LRSAM1-related neuropathies, including painful and predominantly sensory ataxic forms.

Identifiants

pubmed: 30996334
doi: 10.1038/s41431-019-0403-8
pii: 10.1038/s41431-019-0403-8
pmc: PMC6777460
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Cell Cycle Proteins 0
MAD2L1BP protein, human 0
Nuclear Proteins 0
LRSAM1 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1406-1418

Références

Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet. 1974;6:98–118.
doi: 10.1111/j.1399-0004.1974.tb00638.x
Pareyson D, Marchesi CDiagnosis. natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009;8:654–67.
doi: 10.1016/S1474-4422(09)70110-3
Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain. 1980;103:259–80.
doi: 10.1093/brain/103.2.259
Berciano J, García A, Gallardo E, Peeters K, Pelayo-Negro AL, Álvarez-Paradelo S, et al. Intermediate Charcot-Marie-Tooth disease: an electrophysiological reappraisal and systematic review. J Neurol. 2017;264:1655–77.
doi: 10.1007/s00415-017-8474-3
Pisciotta C, Shy ME. Neuropathy. Neuromolecular Med. 2018;148:653–65.
Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol. 2013;9:562–71.
doi: 10.1038/nrneurol.2013.179
Hakonen JE, Sorrentino V, Avagliano Trezza R, de Wissel MB, van den Berg M, Bleijlevens B, et al. LRSAM1-mediated ubiquitylation is disrupted in axonal Charcot-Marie-Tooth disease 2P. Hum Mol Genet. 2017;26:2034–41.
doi: 10.1093/hmg/ddx089
Guernsey DL, Jiang H, Bedard K, Evans SC, Ferguson M, Matsuoka M, et al. Mutation in the gene encoding ubiquitin ligase LRSAM1 in patients with Charcot-Marie-Tooth disease. PLoS Genet. 2010;6:e1001081.
doi: 10.1371/journal.pgen.1001081
Weterman MA, Sorrentino V, Kasher PR, Jakobs ME, van Engelen BG, Fluiter K, et al. A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy. Hum Mol Genet. 2012;21:358–70.
doi: 10.1093/hmg/ddr471
Nicolaou P, Cianchetti C, Minaidou A, Marrosu G, Zamba-Papanicolaou E, Middleton L, et al. A novel LRSAM1 mutation is associated with autosomal dominant axonal Charcot-Marie-Tooth disease. Eur J Hum Genet. 2013;21:190–4.
doi: 10.1038/ejhg.2012.146
Engeholm M, Sekler J, Schöndorf DC, Arora V, Schittenhelm J, Biskup S, et al. A novel mutation in LRSAM1 causes axonal Charcot-Marie-Tooth disease with dominant inheritance. BMC Neurol. 2014;14:118.
doi: 10.1186/1471-2377-14-118
Peeters K, Palaima P, Pelayo-Negro AL, García A, Gallardo E, García-Barredo R, et al. Charcot-Marie-Tooth disease type 2G redefined by a novel mutation in LRSAM1. Ann Neurol. 2016;80:823–33.
doi: 10.1002/ana.24775
Hu B, Arpag S, Zuchner S, Li J. A novel missense mutation of CMT2P alters transcription machinery. Ann Neurol. 2016;80:834–45.
doi: 10.1002/ana.24776
Zhao G, Song J, Yang M, Song X, Liu X. A novel mutation of LRSAM1 in a Chinese family with Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2018;23:55–9.
doi: 10.1111/jns.12247
Sommer CL, Brandner S, Dyck PJ, Harati Y, LaCroix C, Lammens M, et al. Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. J Peripher Nerv Syst. 2010;15:164–75.
doi: 10.1111/j.1529-8027.2010.00276.x
Bacquet J, Stojkovic T, Boyer A, Martini N, Audic F, Chabrol B, et al. Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation. BMJ Open. 2018;8:e021632.
doi: 10.1136/bmjopen-2018-021632
Masingue M, Perrot J, Carlier RY, Piguet-Lacroix G, Latour P, Stojkovic T. WES homozygosity mapping in a recessive form of Charcot-Marie-Tooth neuropathy reveals intronic GDAP1 variant leading to a premature stop codon. Neurogenetics. 2018;19:67–76.
doi: 10.1007/s10048-018-0539-7
Chahin N, Sorenson EJ. Serum creatine kinase levels in spinobulbar muscular atrophy and amyotrophic lateral sclerosis. Muscle Nerve. 2009;40:126–9.
doi: 10.1002/mus.21310
Luigetti M, Modoni A, Renna R, Silvestri G, Ricci E, Montano N, et al. A case of CMT 1B due to Val 102/fs null mutation of the MPZ gene presenting as hyperCKemia. Clin Neurol Neurosurg. 2010;112:794–7.
doi: 10.1016/j.clineuro.2010.05.001
Berciano J, García A, Peeters K, Gallardo E, De Vriendt E, Pelayo-Negro AL, et al. NEFL E396K mutation is associated with a novel dominant intermediate Charcot-Marie-Tooth disease phenotype. J Neurol. 2015;262:1289–300.
doi: 10.1007/s00415-015-7709-4
Aerts MB, Weterman AJ, Quadri M, Schelhaas HJ, Bloem BR, Esselink RA, et al. A LRSAM1 mutation links Charcot-Marie-Tooth type 2 to Parkinson's disease. Ann Clin Transl Neurol. 2015;3:146–9.
doi: 10.1002/acn3.281
Tang B, Seredenina T, Coppola G, Kuhn A, Geschwind DH, Luthi-Carter R, et al. Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Neurobiol Dis. 2011;42:459–67.
doi: 10.1016/j.nbd.2011.02.008
Trempe JF, Sauvé V, Grenier K, Seirafi M, Tang MY, Ménade M, et al. Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science. 2013;340:1451–5.
doi: 10.1126/science.1237908
Bogdanik LP, Sleigh JN, Tian C, Samuels ME, Bedard K, Seburn KL, et al. Loss of the E3 ubiquitin ligase LRSAM1 sensitizes peripheral axons to degeneration in a mouse model of Charcot-Marie-Tooth disease. Dis Model Mech. 2013;6:780–92.
doi: 10.1242/dmm.010942
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425–79.
doi: 10.1146/annurev.biochem.67.1.425
Amit I, Yakir L, Katz M, Zwang Y, Marmor MD, Citri A, et al. Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev. 2004;18:1737–52.
doi: 10.1101/gad.294904

Auteurs

Alessia Peretti (A)

AP-HP, G-H Pitié-Salpêtrière, Centre de Référence des Maladies neuromusculaires, Paris Nord/Est/Ile de france, Paris, France. alessia.peretti@libero.it.
Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. alessia.peretti@libero.it.

Maud Perie (M)

Service de Neurologie CHU Gabriel Montpied, Clermont Ferrand, France.

Didier Vincent (D)

Service de Neurologie, Groupe Hospitalier La Rochelle-Ré-Aunis, La Rochelle, France.

Françoise Bouhour (F)

Hôpital Neurologique Pierre Wertheimer, Service d'ENMG-Pathologies Neuromusculaires, Lyon-Bron, France.

Klaus Dieterich (K)

Service de Génétique Clinique, Hôpital Couple Enfant, CHU Grenoble Alpes, Grenoble, France.

Martial Mallaret (M)

Centre de Compétences des Maladies Neuro Musculaires, CHU Grenoble Alpes, Grenoble, France.

Fanny Duval (F)

Département de Neurologie, CHU Bordeaux (Pellegrin Hospital), Bordeaux, France.

Cyril Goizet (C)

Centre de Référence neurogénétique, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France.
Laboratoire MRGM, INSERM U1211, Univ. Bordeaux, Bordeaux, France.

Raul Juntas-Morales (R)

Département de Neurologie, CHU de Montpellier, Montpellier, France.

Laurent Magy (L)

Service et Laboratoire de Neurologie, Centre de Référence Neuropathies Périphériques rares, CHU Limoges, Limoges, France.

Guilhem Solé (G)

Département de Neurologie, CHU Bordeaux (Pellegrin Hospital), Bordeaux, France.

Sylvain Nollet (S)

Service Explorations et Pathologies Neuromusculaires, CHRU Besançon, Besançon, France.

Adeline Not (A)

AP-HP, Service de Neurologie, CHU Bicêtre, Le Kremlin-Bicêtre, France.
Centre de Référence national des Neuropathies amyloïdes familiales et Autres Neuropathies périphériques rares (NNERF), Le Kremlin-Bicêtre, France.

Sarah Léonard-Louis (S)

AP-HP, G-H Pitié-Salpêtrière, Centre de Référence des Maladies neuromusculaires, Paris Nord/Est/Ile de france, Paris, France.

Bruno Francou (B)

AP-HP, Bicêtre Paris Sud Hospital, Service Génétique moléculaire pharmacogénétique et Hormonologie, Le Kremlin-Bicêtre, France.

Eric Leguern (E)

Département de Génétique, AP-HP, Sorbonne Université, Paris, France.
Hôpital Pitié-Salpêtrière, Paris, France.

Anne-Sophie Lia (AS)

Univ. Limoges, CHU Limoges, Limoges, France.

Corinne Magdelaine (C)

Univ. Limoges, CHU Limoges, Limoges, France.

Philippe Latour (P)

Service de Biochimie et Biologie moléculaire Grand Est, Unité Médicale Pathologies neurologiques et cardiologiques, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Bron, France.

Tanya Stojkovic (T)

AP-HP, G-H Pitié-Salpêtrière, Centre de Référence des Maladies neuromusculaires, Paris Nord/Est/Ile de france, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH